Decoy Therapeutics Inc. SEC filings DCOY

Decoy Therapeutics Inc. has 743 filings in SEC EDGAR's recent list, going back to Aug 6, 2014. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 23, 2026 (material agreement, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
10-K/A Amended annual report Apr 30, 2026 Dec 31, 2025
10-K Annual report Mar 31, 2026 Dec 31, 2025
10-K Annual report Mar 21, 2025 Dec 31, 2024
10-K/A Amended annual report Apr 22, 2024 Dec 31, 2023
10-K Annual report Mar 22, 2024 Dec 31, 2023
10-K Annual report Mar 27, 2023 Dec 31, 2022
10-K Annual report Mar 25, 2022 Dec 31, 2021
10-K Annual report Mar 18, 2021 Dec 31, 2020
10-K Annual report Mar 23, 2020 Dec 31, 2019
10-K/A Amended annual report Apr 16, 2019 Dec 31, 2018
10-K Annual report Mar 6, 2019 Dec 31, 2018
10-K Annual report Mar 7, 2018 Dec 31, 2017
10-K Annual report Mar 8, 2017 Dec 31, 2016
10-K Annual report Mar 8, 2016 Dec 31, 2015
10-K Annual report Mar 24, 2015 Dec 31, 2014

Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
DCOY (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Houston, TX
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1615219
Former names
Salarius Pharmaceuticals, Inc. (until Jan 9, 2026); Flex Pharma, Inc. (until Jul 22, 2019)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.